Provided are antibodies that bind to bacteria associated with necrotizing enterocolitis (NEC), methods of detecting the same, and methods of using the same for treating and/or preventing NEC. The antibodies that bind to bacteria associated with NEC are detected by, e.g., detecting binding of the antibody to a bacterium in a bacterial array that includes the bacteria associated with NEC.

A method to predict the risk of eczema is provided based on differences in the development of microbiota and its metabolites in healthy infants and infants that develop eczema, and nutritional remedies based on this finding, in the form of lactate utilizing bacteria and fibres stimulating lactate utilizing bacteria.

The application is about a method for diagnosing autism spectrum disorder (ASD) in a human subject, comprising providing a device comprising a reagent for determining the concentration of arginine vasopressin (AVP) in a biological sample from the subject; and measuring the concentration of AVP in the sample using the device. Disclosed is also a method for diagnosing ASD, comprising providing a first device comprising a reagent for determining a concentration of AVP and a second device comprising a reagent for determining a concentration of one or more analytes selected from arginine vasopressin receptor 1a and oxytocin receptor, to determine the concentrations of AVP and of the one or more analytes. Disclosed is also a method of predicting severity of ASD in a male human subject, comprising providing a device for determining the concentration of AVP in cerebrospinal fluid, said device comprising a reagent for determining presence or absence of AVP; and measuring the concentration of AVP in a biological sample from the subject using the device. Disclosed is also a method of predicting likelihood of an ASD in a human subject, comprising providing a device for determining the concentration of AVP in cerebrospinal fluid, said device comprising a reagent for determining presence or absence of AVP; and measuring the concentration of AVP in cerebrospinal fluid using the device.

The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

The present invention is related to the in vitro use of lyso-Gb1 as a draggable target in the development of a drug, and to antagonist of lyso-Gb1 for use in the treatment and/or prevention of a disease, wherein the disease is Gaucher disease or Parkinson's disease.

A correlative finding between increased Clostridiales and/or Bifidobacteriales bacterial abundance in the gut and intestinal barrier maturation of preterm neonates at-risk for development of necrotizing enterocolitis (NEC) is disclosed. These findings form the basis for the methods of identifying preterm infants at risk for developing necrotizing enterocolitis (NEC), the methods of treating such infants, as well as the methods of characterizing intestinal permeability in preterm infants disclosed herein.

Methods for predicting canine hip dysplasia (CHD) in an immature canine subject are provided. The methods include the use of concentration profiles of a plurality of polypeptides, including C2C, CTX-I, CTX-II, RANKL, PIICP, COMP, PINP. Also provided are CHD biomarker profiles for predicting or diagnosing CHD in immature or young canines before CHD develops. Diagnostic reagents and kits for the same are also provided.

Early detection of lysosomal storage diseases (LSDs) including Mucopolysaccharidosis Type I (MPS I) and Pompe Disease can greatly improve patient outcome as each disease can be fatal once symptoms emerge. Screening for MPS I and Pompe Disease using biological samples including dried blood spots (DBS), buccal swab, peripheral blood mononuclear cells (PBMCs), or white blood cells (WBCs) is described. The disclosed methods and assays provide a robust way to screen newborns for LSDs. The disclosed methods and assays can also allow rapid prediction of whether a patient with LSD will develop an immune response to enzyme replacement therapy (ERT), thus improving treatment for patients with LSDs. The disclosed methods and assays can also further reduce the number of false positives caused by pseudo deficiency cases of LSD, such as MPS I and Pompe Disease.

The present invention provides methods to determine whether a patient with a lysosomal storage disorder will benefit from treatment with a specific pharmacological chaperone. The present invention exemplifies an in vitro method for determining α-galactosidase A responsiveness to a pharmacological chaperone such as 1-deoxygalactonojirimycin in a cell line expressing a mutant from of α-galactosidase A. The invention also provides a method for diagnosing Fabry disease in patients suspected of having Fabry disease.

Provided is an isolated antibody that specifically binds to HPA-1a. Also provided is a nucleic acid molecule that encodes the antibody, and compositions comprising the antibody. Also provided is a method of producing the antibody and methods and uses which employ the antibody. Also provided are therapeutic uses of the antibody, for example in the treatment or prophylaxis of fetal and neonatal alloimmune thrombocytopenia (FNAIT).